This study will evaluate if Eloctate is superior to Emicizumab in reducing inhibitors in
children with severe hemophilia when given before the first bleed (preemptive) and continued
weekly to prevent bleeds (prophylaxis); and whether Eloctate immune tolerance induction (ITI)
plus emicizumab is superior to Eloctate ITI alone in eradicating inhibitor formation in
children and adults with severe hemophilia A.
Phase:
Phase 3
Details
Lead Sponsor:
Margaret Ragni University of Pittsburgh
Treatments:
Antibodies, Bispecific Factor VIII Immunoglobulin Fc Fragments